“Steve Jones of Aspen Capital was instrumental in the growth and development of NeoGenomics. Aspen closed its first investment in 2003 and continued to invest for years as the Company required growth capital. In addition, Steve was deeply involved in helping NeoGenomics refine its business model and strategy, and execute many strategic initiatives. Today, NeoGenomics is a recognized leader in Oncology Diagnostics with a multi-billion dollar market capitalization and Steve served as a trusted member of our Board for over 15 years.”